These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35032384)

  • 1. Biochemical Assessment of Cardiovascular Risk Associated with the Duration of Antipsychotic Therapy in Patients with Schizophrenia.
    Akande AA; Adelekan A; Abdulazeez IM
    West Afr J Med; 2021 Dec; 38(12):1156-1161. PubMed ID: 35032384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.
    Huang TL; Chen JF
    Schizophr Res; 2005 Dec; 80(1):55-9. PubMed ID: 15964176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment.
    Zhai D; Cui T; Xu Y; Feng Y; Wang X; Yang Y; Li S; Zhou D; Dong G; Zhao Y; Yang Y; Zhang R
    Schizophr Res; 2017 Jan; 179():41-49. PubMed ID: 27613506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between dyslipidaemia and types of antipsychotic medications among patients with chronic schizophrenia.
    Ruzanna ZZ; Ong LY; Cheah YC; Fairuz A; Marhani M
    Med J Malaysia; 2012 Feb; 67(1):39-44. PubMed ID: 22582547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia.
    Onen S; Taymur I
    J Psychopharmacol; 2021 Sep; 35(9):1120-1126. PubMed ID: 34176366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Schizophrenia, diabetes mellitus and antipsychotics].
    Gury C
    Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.
    Jena M; Mishra A; Mishra BR; Nath S; Maiti R
    Psychopharmacology (Berl); 2020 Nov; 237(11):3471-3480. PubMed ID: 32740676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
    Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).
    Barnett AH; Millar HL; Loze JY; L'Italien GJ; van Baardewijk M; Knapp M
    Eur Arch Psychiatry Clin Neurosci; 2009 Jun; 259(4):239-47. PubMed ID: 19267255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.
    Van Gaal LF
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S142-8. PubMed ID: 16863690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.
    Barnett AH; Mackin P; Chaudhry I; Farooqi A; Gadsby R; Heald A; Hill J; Millar H; Peveler R; Rees A; Singh V; Taylor D; Vora J; Jones PB
    J Psychopharmacol; 2007 Jun; 21(4):357-73. PubMed ID: 17656425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs.
    Darbà J; Kaskens L; Aranda P; Arango C; Bobes J; Carmena R; Rejas J
    Ann Clin Psychiatry; 2013 Feb; 25(1):17-26. PubMed ID: 23376866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risks of atypical antipsychotic drug treatment.
    Drici MD; Priori S
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
    Brandt L; Schneider-Thoma J; Siafis S; Efthimiou O; Bermpohl F; Loncar L; Neumann K; Hasan A; Heinz A; Leucht S; Gutwinski S
    Lancet Psychiatry; 2022 Mar; 9(3):232-242. PubMed ID: 35183280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
    Hasnain M; Fredrickson SK; Vieweg WV
    J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.